CN111875558B - Thiazolidine derivative and application thereof in depression resistance - Google Patents
Thiazolidine derivative and application thereof in depression resistance Download PDFInfo
- Publication number
- CN111875558B CN111875558B CN202010855736.2A CN202010855736A CN111875558B CN 111875558 B CN111875558 B CN 111875558B CN 202010855736 A CN202010855736 A CN 202010855736A CN 111875558 B CN111875558 B CN 111875558B
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- pharmaceutically acceptable
- antidepressant
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000003548 thiazolidines Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 17
- 229940005513 antidepressants Drugs 0.000 claims abstract description 15
- 230000001430 anti-depressive effect Effects 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims description 19
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 229940125782 compound 2 Drugs 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- JRQJYVACDJEUDZ-UHFFFAOYSA-N 3-(carbamothioylamino)benzoic acid Chemical compound NC(=S)NC1=CC=CC(C(O)=O)=C1 JRQJYVACDJEUDZ-UHFFFAOYSA-N 0.000 claims description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229940125904 compound 1 Drugs 0.000 claims description 5
- 229940126214 compound 3 Drugs 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 claims description 3
- 229960000583 acetic acid Drugs 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- 238000010025 steaming Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 abstract description 2
- 229960000389 fluoxetine hydrochloride Drugs 0.000 abstract description 2
- 150000002611 lead compounds Chemical class 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 34
- 125000000217 alkyl group Chemical group 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 5
- -1 thiazole amine compound Chemical class 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101710114597 Sodium-dependent serotonin transporter Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- 102000009346 Adenosine receptors Human genes 0.000 description 3
- 108050000203 Adenosine receptors Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- KBBNRJXVAZHGBA-UHFFFAOYSA-N 3-[(4-phenyl-1,3-thiazol-2-yl)amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2SC=C(N=2)C=2C=CC=CC=2)=C1 KBBNRJXVAZHGBA-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000009493 Neurokinin receptors Human genes 0.000 description 1
- 108050000302 Neurokinin receptors Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 1
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000006341 heptafluoro n-propyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)* 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a thiazolamine derivative with antidepressant activity, which can be used for preparing antidepressant drugs, widens the range of the existing antidepressant compounds, and can be continuously optimized as a lead compound. Compared with fluoxetine hydrochloride, the compound of the invention has better antidepressant activity. The compound has simple preparation route and mild condition, and is easy for industrialized mass production.
Description
Technical Field
The invention relates to the field of medicinal chemistry, in particular to a series of thiazolamine derivatives, and a preparation method and application thereof.
Background
Depression is a disease clinically manifested as mood disorders or affective disorders due to various causes, and about 15% of patients have suicidal tendency, which greatly affects social stability and economic development. Receptors are currently thought to play an important role in the pathogenesis of depression and the mechanism of antidepressants, and the receptors involved are monoamine transmitter receptors, glutamate receptors, glucocorticoid receptors, neurokinin receptors, and the like. Monoamine transmitter receptors include 5-hydroxytryptamine (5-HT) receptors, adrenergic receptors, and dopamine receptors, among others, which have been most widely studied as the 5-HT system.
The jensen pharmaceutical industry reported thiazole amine derivatives (CN101263130A) with antidepressant activity, which act by modulating α 7 nicotinic receptors and can be used for antidepressant, anxiolytic, hypnotic, etc., said compounds having the general structure as follows:
however, no thiazole amine antidepressant on the market exists at present, so that the development of a novel thiazole amine compound with antidepressant activity still has good application prospect.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: a class of thiazolamine derivatives is provided which are useful as antidepressants.
In a first aspect, the present invention provides compounds of formula I and pharmaceutically acceptable salts thereof, having the following structure:
wherein: r1Each independently selected from H, halogen, -OH, -NO2, -CN, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy;
R2selected from hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy;
n is selected from 0, 1, 2,3 or 4.
Preferably, R1Each independently selected from H, halogen, -OH, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, more preferably H; n is selected from 0, 1 or 2, preferably 0 or 1.
Preferably, R2Selected from hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, more preferably H.
More preferably, the compounds of formula I according to the invention are selected from the following compounds:
in another aspect of the invention there is provided a process for the preparation of a compound of formula I, the reaction scheme being as follows:
wherein R is1、R2And n is as defined above.
The preparation method of the invention specifically comprises the following reaction steps:
the method comprises the following steps: adding 3-carboxyphenylthiourea, the compound 1 and glacial acetic acid into a reaction bottle, uniformly stirring, heating to reflux, removing insoluble solids in the reaction bottle when the reaction is finished, rotationally evaporating partial solvent, cooling in a ventilation kitchen at normal temperature, separating out solids, filtering, and drying the obtained solids to obtain the intermediate compound 2.
Step two: adding substituted aniline (compound 3), an intermediate compound 2 and dichloromethane into a reaction bottle, stirring and dissolving at room temperature, adding 4-dimethylaminopyridine, stirring and reacting for 0.5-1h, adding DCC, detecting by TLC, filtering to remove part of dicyclohexylurea after the reaction is finished, and purifying by column chromatography to obtain a target product I.
Preferably, the molar ratio of the 3-carboxyphenylthiourea in step one to the compound 1 is from 1:1 to 1.2, preferably 1:1.
Preferably, the molar ratio of intermediate compound 2 to substituted aniline (compound 3) in step two is 1:1-2, preferably 1: 1.5.
In another aspect of the present invention, a pharmaceutical composition is provided, which comprises the compound represented by formula I or a pharmaceutically acceptable salt thereof described in the present invention, and a pharmaceutically acceptable carrier or excipient.
Another aspect of the invention relates to the use of a compound of the invention, or a pharmaceutical composition comprising said compound, in the manufacture of an antidepressant medicament.
Defining:
"alkyl" means consisting solely of carbon and hydrogen atoms, containing no unsaturation, and may be a C1-6 alkyl group. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. Representative saturated straight chain alkyl groups include, but are not limited to-methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and-n-hexyl; and saturated branched alkyl groups include, but are not limited to-isopropyl, -sec-butyl, -isobutyl, -tert-butyl, -isopentyl, 2-methylbutyl, 3-methylbutyl, 2-methyl-pentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-dimethyl-butyl, and the like. The alkyl group is attached to the parent molecule by a single bond. Unless stated otherwise in the specification, an alkyl group is optionally substituted with one or more substituents independently including: acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl. In a non-limiting embodiment, the substituted alkyl group can be selected from the group consisting of fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, benzyl, and phenethyl.
"alkoxy" means an "alkyl" group attached to the parent molecule through an oxygen atom, wherein "alkyl" has the meaning described above.
"haloalkyl" refers to an alkyl group wherein all hydrogen atoms are partially or fully replaced with a halogen selected from fluoro, chloro, bromo, and iodo. In some embodiments, all hydrogen atoms are each replaced with fluoro groups. In some embodiments, all hydrogen atoms are each replaced with a chloro group. Examples of haloalkyl groups include-CF 3, -CF2CF3, -CF2CF2CF3, -CFCl2, -CF2Cl, and the like.
In certain embodiments, the pharmaceutically acceptable form is a pharmaceutically acceptable salt, which is well known in the art. Examples of pharmaceutically acceptable salts are such as hydrochloric, hydrobromic, phosphoric, sulfuric, perchloric, acetic, oxalic, maleic, tartaric, citric, succinic or malonic, acetic, propionic, glycolic, pyruvic, oxalic, lactic, trifluoroacetic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, salicylic, and the like.
"pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coating agents, isotonic and absorption delaying agents and the like. Pharmaceutically acceptable carriers or excipients do not destroy the pharmacological activity of the disclosed compounds and are non-toxic when administered in a dose sufficient to deliver a therapeutic amount of the compound. The use of such media and agents for pharmaceutically active substances is well known in the art.
Compared with the prior art, the invention has the beneficial effects that:
(1) the invention provides a new thiazolamine derivative with antidepressant activity, widens the range of the existing antidepressant compound, and can be continuously optimized as a lead compound;
(2) compared with fluoxetine hydrochloride, the compound of the invention has better antidepressant activity.
(3) The compound has simple preparation route and mild condition, and is easy for industrialized mass production.
Detailed Description
The present invention will be described in detail with reference to examples. In the present invention, the following examples are intended to better illustrate the present invention and are not intended to limit the scope of the present invention. The materials, reagents and the like used in the examples are commercially available unless otherwise specified.
Example 13- [ (5-Ethyl-4-phenylthiazol-2-yl) amino ] benzoic acid
The method comprises the following steps: 3- [ (-4-phenylthiazol-2-yl) amino ] benzoic acid
1.96g (0.01mol) of 3-carboxyphenylthiourea, 1.99g (0.01mol) of 2-bromo-1-phenylethanone and 15mL of glacial acetic acid were added to a 100mL inclined-mouth reaction flask with a condenser tube, stirred uniformly, heated to reflux, and reacted for about 24 hours while monitoring the progress of the reaction by TLC (developing agent: ethyl acetate: petroleum ether: 4: 1). The insoluble solid in the reaction flask was removed while hot and part of the solvent was rotary evaporated. The mixture was cooled in a fume hood at room temperature to precipitate a solid, which was then filtered and dried to obtain 2.02g of powder with a yield of 68.2%.1H NMR(DMSO-D6,400MHz),δ:7.16(s,1H,CH-S),7.30-8.24(m,9H,C6H4,C6H5),10.38(s,1H,COOH)。
Step two: preparation of Compounds of formula I
Adding aniline (0.28g, 3mmol), intermediate compound 2 (0.59g, 2mmol) and 20mL dichloromethane into a reaction bottle, stirring at room temperature for dissolving, adding 2mmol 4-dimethylaminopyridine, stirring for reacting for 0.5h, adding 2mmol DCC, detecting by TLC (petroleum ether: ethyl acetate: 5:1), filtering to remove part of dicyclohexylurea after the reaction is finished, and purifying by column chromatography to obtain 0.58g of target product I with the yield of 78.4%.
1H NMR(DMSO-D6,400MHz),δ:7.16(s,1H,CH-S),7.28-8.27(m,14H,C6H4,C6H5,C6H5)。ESI-MS(m/z):371.1。
Example 2 antidepressant Activity test
This experiment searches for compounds that act directly on or produce reuptake inhibitory effects through adenosine receptors by creating a high-throughput hoofed segment of fluorescent substance ASP. The fluorescent dye ASP + is a compound with neurotoxicity, can be combined with a monoamine transporter to enter a cell and emit yellow fluorescence (the combination strength is in the sequence of dopamine transporter > epinephrine transporter >5-HT transporter). When other compounds capable of binding to the transporter exist, competition with ASP is performed, so that the number of cells entering the cells is reduced, yellow fluorescence is weakened, and a reuptake inhibitor acting on the 5-HT transporter is screened by comparing the change of fluorescence intensity.
RBL cells are a cell line that can secrete histamine and 5-HT, are immortalized mast cells, and can release transmitters in quanta. And has the ability to undergo 5-HT reuptake.
CACO-2 cells are adenocarcinoma cell strains derived from human small intestines, and research shows that the cells after being cultured and differentiated for a period of time can express various transporters and receptors, such as SERT, adenosine receptors and the like. By establishing a standardized process of cell culture, cells can be well differentiated after being cultured for 6-7 days, a test sample to be selected is added for a period of time, then fluorescent dye is added according to a certain concentration, the dye which does not enter the cells is absorbed, and then the fluorescence intensity of ASP between different samples is compared, so that a sample which directly inhibits SERT activity or indirectly affects the activity of a transporter through the action of activating/inhibiting an adenosine receptor can be found.
1) Cell culture
RBL cell lines were purchased from the China center for type culture Collection. The cell line used was EMEM containing 1.5g/L sodium bicarbonate, 0.1mM non-essential amino acids, 1.0mM sodium pyruvate, 2mM L-glutamine and Earle' BSS, 85%; cell culture was performed with heat-inactivated FBS 15% medium. The cells need to be changed every other day by 1 time, and when the cell proliferation reaches 80%, the cells need to be passaged with the ratio of 1: 3.
Strictly performing aseptic operation, performing cell culture in MEM alpha complete culture medium containing 15% fetal calf serum, performing experiment when the cells reach good logarithmic phase, washing twice with D-hanks solution, adding 0.125% pancreatin digested cells, standing at 37 deg.C for 5min to make intercellular connection and propagation, distributing cells singly, adding equal volume of complete culture medium to stop digestion, blowing gently to blow cells to centrifuge the suspension into a centrifuge tube, discarding supernatant, suspending the cells with complete culture medium, counting, and diluting the cells to 6 × 105one/mL for use.
Cell plating and dosing, addition of fluorescent dye: 4X 105Adding the cell suspension/mL into a 96-well plate according to 0.1 mL/well, performing a high-throughput screening experiment by using the portable fluorescence device when the cells grow well adherent to the wall for more than 10h, reading at the excitation wavelength of 475nm and the emission wavelength of 605nm, and performing result statistics.
CACO-2 cell strain is preserved in the laboratory of the national drug hoof selection center of the institute of medicine of Chinese academy of medical sciences. The cell line used was EMEM containing 1.5g/L sodium bicarbonate, 0.1mM non-essential amino acids, 1.0mM sodium pyruvate, 2mM L-glutamine and Earle' BSS, 80%; cell culture was performed with heat-inactivated FBS 20% medium. The cells need to be changed every other day by 1 time, and when the cell proliferation reaches 80%, the cells need to be passaged with the ratio of 1: 3.
Cell plating and differentiation: 1X 105Adding the cell sap per mL into a 96-pore plate according to 0.1mL per pore, changing the cell sap every other day when the cells do not grow full, changing the cell sap every day when the cells grow fast and grow full at the bottom, growing microvilli when the cells grow for 6-7 days and are unclear in visible cell boundary, and conducting microvilli growth.
2) Data processing
Calculating the fluorescence intensity inhibition rate:
at a concentration of 10. mu.g/mL, the compounds of the invention inhibit SERT as follows:
the results show that the compound has good inhibitory activity on SERT, can be used for further research and development, and is expected to become a new antidepressant drug.
Claims (7)
3. the method of claim 2, comprising the reaction steps of:
the method comprises the following steps: adding 3-carboxyphenylthiourea, the compound 1 and glacial acetic acid into a reaction bottle, uniformly stirring, heating to reflux, removing insoluble solids in the reaction bottle when the reaction is finished, rotationally steaming part of the solvent, putting the solvent into a ventilation kitchen, cooling at normal temperature, separating out solids, filtering, and drying the obtained solids to obtain an intermediate compound 2;
step two: adding the aniline compound 3, the intermediate compound 2 and dichloromethane into a reaction bottle, stirring and dissolving at room temperature, adding 4-dimethylaminopyridine, stirring and reacting for 0.5-1h, adding DCC, detecting by TLC, reacting, filtering to remove part of dicyclohexylurea after the reaction is finished, and purifying by column chromatography to obtain a target product I.
4. The method of claim 3, wherein:
the mol ratio of the 3-carboxyl phenylthiourea to the compound 1 in the first step is 1: 1-1.2;
in the second step, the molar ratio of the intermediate compound 2 to the aniline compound 3 is 1: 1-2.
5. The method of claim 4, wherein:
the mol ratio of the 3-carboxyl phenylthiourea to the compound 1 in the first step is 1: 1;
in the second step, the molar ratio of the intermediate compound 2 to the aniline compound 3 is 1: 1.5.
6. A pharmaceutical composition comprising a compound of formula I as described in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient.
7. Use of a compound of claim 1 or a pharmaceutical composition of claim 6 in the preparation of an antidepressant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010855736.2A CN111875558B (en) | 2020-08-21 | 2020-08-21 | Thiazolidine derivative and application thereof in depression resistance |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010855736.2A CN111875558B (en) | 2020-08-21 | 2020-08-21 | Thiazolidine derivative and application thereof in depression resistance |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111875558A CN111875558A (en) | 2020-11-03 |
CN111875558B true CN111875558B (en) | 2022-07-01 |
Family
ID=73204087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010855736.2A Expired - Fee Related CN111875558B (en) | 2020-08-21 | 2020-08-21 | Thiazolidine derivative and application thereof in depression resistance |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111875558B (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2566104A1 (en) * | 2004-05-18 | 2005-12-01 | Ab Science | Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons |
CN101263130B (en) * | 2005-09-13 | 2011-03-09 | 詹森药业有限公司 | 2-aniline-4-aryl substituted thiazole derivatives |
CN109320473B (en) * | 2018-10-17 | 2022-11-22 | 南华大学 | Thiazolylaminobenzamide acetic acid derivatives and uses thereof |
-
2020
- 2020-08-21 CN CN202010855736.2A patent/CN111875558B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN111875558A (en) | 2020-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3070089B1 (en) | Aminomethyl tryptanthrin derivative, preparation method and application thereof | |
JP2021130700A (en) | Combination therapy for treating cancer | |
EP4140487A1 (en) | Combination therapy for treating cancer | |
CN107922425A (en) | Method for preparing PARP inhibitor, crystal form and application thereof | |
JP7324144B2 (en) | cancer treatment modalities | |
CN110099900A (en) | For the hedgehog pathway inhibitor of Smoothened mutant strain | |
CN109320473B (en) | Thiazolylaminobenzamide acetic acid derivatives and uses thereof | |
TW201938558A (en) | Crystal form, salt type of pyridoimidazole compound and preparation method thereof | |
US11236112B2 (en) | Crystal form and salt form of TGF-βRI inhibitor and preparation method therefor | |
CN109456279B (en) | Thiazolylaminobenzamide acetate derivatives and uses thereof | |
CN111875558B (en) | Thiazolidine derivative and application thereof in depression resistance | |
CN111909111B (en) | 5-alkyl thiazolamine derivative and application thereof in depression resistance | |
EP1400510B1 (en) | Cyclic diamine compounds having fused-ring groups | |
JP7450017B2 (en) | Predominant salt forms of pyrimidine derivatives and their crystal forms | |
CN108530337B (en) | Indoleamide compound capable of selectively inhibiting gastric cancer cells | |
CN110143893A (en) | A kind of compound, Its Preparation Method And Use that can combine alpha-synuclein aggregation body by force | |
CN109232467B (en) | Thiazole aminobenzoic acid derivative and application thereof | |
EP3287459B1 (en) | Purinyl-n-hydroxyl pyrimidine formamide derivatives, preparation method therefor and use thereof | |
JP6695875B2 (en) | Novel 1,3,5-triazine PI3K inhibitor as anticancer agent and method for producing the same | |
CN108912035B (en) | Indole amide compound with anti-tumor activity | |
EP3677581A1 (en) | Deuterated indoleamine 2,3-dioxygenase inhibitor and application thereof | |
CN102786515A (en) | 2-(2, 2-dimethyl-2, 3-dihydrobenzofuran-5-group)morpholine and preparation method and application | |
CN102633791A (en) | Application of 4-alkyl-6-aryl-5-(1,2,4-triazole-1-yl)-2-amino-1,3-thiazine to preparation of antidepressants | |
CN115475253B (en) | Lapatinib-cancer cell stem inhibitor conjugate, preparation method, pharmaceutical composition and application | |
WO2024109937A1 (en) | Pharmaceutically acceptable salt of quinoline amine compound, and crystal form thereof and preparation method therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220701 |